Evidentiary Considerations for Integration of Biomarkers in Drug Development Symposium Evidentiary Considerations for Integration of Biomarkers in Drug Development Symposium On August 21st, the University of Maryland&
Collaboration is Making LIFE Better: Critical Path Institute Celebrates Key Milestones AZ Bionindustry Association
Critical Path Institute’s Polycystic Kidney Disease Outcomes Consortium Secures FDA Qualification for Enrichment Biomarker in Autosomal Dominant Polycystic Kidney Disease (ADPKD) August 31, 2015 Critical Path Institute’s Polycystic Kidney Disease Outcomes Consortium Secures FDA Qualification for Enrich
AZBio Honors Lynn Hudson, Ph.D. Of Critical Path Institute As 2015 Arizona Bioscience Leader August 19, 2015 AZBio Honors Lynn Hudson, Ph.D. Of Critical Path Institute As 2015 Arizona Bioscience Leader August 19, 2015 – C
New Clinical Infectious Diseases Journal Supplement Highlights Hollow Fiber System Model for Tuberculosis New Clinical Infectious Diseases Journal Supplement Highlights Hollow Fiber System Model for Tuberculosis The achievements
Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool
